Q3 2023 Holdings
Filed 2023-11-14 | 32 holdings | $374.6M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Cullinan Oncology, Inc.(CGEM) | Common | 230031106 | $69.2M | 7,648,268 | 18.5% |
| Olema Pharmaceuticals, Inc.(OLMA) | Common | 68062P106 | $22.9M | 1,857,681 | 6.1% |
| Geron Corporation(GERN) | Common | 374163103 | $22.7M | 10,712,481 | 6.1% |
| Repare Therapeutics, Inc.(RPTX) | Common | 760273102 | $19.8M | 1,639,849 | 5.3% |
| iTeos Therapeutics, Inc.(5E7) | Common | 46565G104 | $19.1M | 1,745,943 | 5.1% |
| Intellia Therapeutics, Inc.(NTLA) | Common | 45826J105 | $17.2M | 544,639 | 4.6% |
| Moonlake Immunotherapeutics(MLTX) | Common | 61559X104 | $16.8M | 294,190 | 4.5% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $15.0M | 3,287,397 | 4.0% |
| Crinetics Pharmaceuticals Inc.(CRNX) | Common | 22663K107 | $14.2M | 479,053 | 3.8% |
| Insmed Incorporated(INSM) | Common | 457669307 | $13.3M | 527,458 | 3.6% |
| Structure Therapeutics Inc(GPCR) | Common | 86366E106 | $11.6M | 230,761 | 3.1% |
| Verve Therapeutics, Inc | Common | 92539P101 | $11.4M | 857,940 | 3.0% |
| Relay Therapeutics Inc.(RLAY) | Common | 75943R102 | $11.4M | 1,352,133 | 3.0% |
| Regenxbio Inc.(RGNX) | Common | 75901B107 | $10.8M | 656,718 | 2.9% |
| Cymabay Therapeutics Inc(CBAYUSD) | Common | 23257D103 | $9.1M | 610,770 | 2.4% |
| Karuna Therapeutics Inc | Common | 48576A100 | $9.0M | 53,210 | 2.4% |
| Amicus Therapeutics Inc.(FOLD) | Common | 03152W109 | $8.7M | 716,139 | 2.3% |
| Revolution Medicines, Inc.(RVMD) | Common | 76155X100 | $7.6M | 273,408 | 2.0% |
| Xeris Biopharma Holdings Inc(XERS) | Common | 98422E103 | $7.4M | 3,987,967 | 2.0% |
| Avadel Pharmaceuticals PLC | Common | 05337M104 | $6.8M | 664,224 | 1.8% |
| Axsome Therapeutics, Inc.(AXSM) | Common | 05464T104 | $6.5M | 93,586 | 1.7% |
| Madrigal Pharmaceuticals inc(MDGL) | Common | 558868105 | $6.0M | 40,859 | 1.6% |
| Kalvista Pharmaceuticals Inc(KALV) | Common | 483497103 | $5.6M | 577,958 | 1.5% |
| Werewolf Therapeutics, Inc.(HOWL) | Common | 95075A107 | $5.1M | 2,388,011 | 1.4% |
| Travere Therapeutics Inc.(TVTX) | Common | 89422G107 | $4.9M | 552,846 | 1.3% |
| Morphic Holding Inc | Common | 61775R105 | $4.6M | 200,000 | 1.2% |
| Adaptimmune Therapeutics plc(ADAPY) | Sponsored ADR | 00653A107 | $4.0M | 5,095,912 | 1.1% |
| Viridian Therapeutics Inc(VRDN) | Common | 92790C104 | $3.9M | 255,323 | 1.0% |
| Phathom Pharmaceuticals inc(PHAT) | Common | 71722W107 | $3.6M | 347,332 | 1.0% |
| Viking Therapeutics Inc(VKTX) | Common | 92686J106 | $3.6M | 325,000 | 1.0% |
| Inozyme Pharma Inc. | Common | 45790W108 | $1.4M | 326,921 | 0.4% |
| Harpoon Therapeutics, Inc. | Common | 41358P205 | $1.3M | 319,670 | 0.3% |